Company Quick10K Filing
TCR2 Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 24 $399
10-Q 2019-11-12 Quarter: 2019-09-30
10-Q 2019-08-09 Quarter: 2019-06-30
10-Q 2019-05-13 Quarter: 2019-03-31
10-K 2019-03-29 Annual: 2018-12-31
S-1 2018-12-28 Public Filing
8-K 2019-11-12 Earnings, Exhibits
8-K 2019-08-08 Earnings, Exhibits
8-K 2019-05-13 Earnings, Exhibits
8-K 2019-04-01 Earnings, Exhibits
8-K 2019-02-26 Other Events, Exhibits
8-K 2019-02-19 Amend Bylaw, Exhibits

TCR2 Therapeutics Financials

TCRR Metrics, Comps, Filings

Annual | Quarterly

Business

We are a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. Our proprietary TCR Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex, which we believe is essential for T cell therapies to be effective in patients with solid tumors.

We have designed our TRuC-T cells so that tumor cell recognition does not require human leukocyte antigens (HLA), which provides two important additional benefits. First, in contrast to current engineered T cell therapies that use the full TCR (TCR-T cells), our technology is designed so that it can be applied to all patients that express the cancer surface antigen irrespective of HLA subtype, which we believe will allow us to address a significantly larger patient population. Second, HLA is downregulated or lost in many tumors which can prevent their recognition by T cells and lead to diminished response rates and higher relapse rates. We therefore believe our approach will allow us to deliver the first HLA-independent TCR-T cell therapy for patients with solid tumors. We also believe that our product candidates have the potential to improve upon the efficacy and safety of currently approved chimeric antigen receptor T (CAR-T) cell therapies in CD19-positive B-cell hematological malignancies. This belief is based on preclinical studies comparing our product candidates to CAR-T cells that we engineered.

According to a 2017 press release from the FDA on the licensure of the first engineered T cell therapy for cancer, the field is "entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer." We founded our company to build on these early T cell therapy innovations while addressing their limitations and making our product candidates available to a broader patient population.


Valuation ($)

Market Cap, Enterprise Value

Balance Sheet ($)

Assets, Stockholders' Equity

Income Statement ($ Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($ Annual)

Operating, Investing, Financing

Comps ($ TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Aegean Marine Petroleum Network (ANW) 451,437,849,000 0% 1,600,933,000,000 1,011,342,000,000 0 0 0 0 929,118,849,000
Perry Ellis (PERY) 436,499,190,000 38% 5.6 9% 554,666,000,000 169,797,000,000 880,665,000,000 332,305,000,000 49,882,000,000 74,302,000,000 415,161,189,000
Invesco DB Agriculture Fund (DBA) 425,450,000,000 -24.2 -4% 425,328,266,000 5,098,589,000 0 0 -17,565,344,000 -17,506,264,000 423,702,422,000
GraniteShares Gold Trust (BAR) 414,764,800,000 7.4 10% 545,586,000,000 75,000,000 0 0 55,958,000,000 55,958,000,000 414,764,800,000
Stellar Acquisition III (STLR) 408,741,648,000 13% -26.5 -51% 31,016,000,000 22,873,000,000 41,708,000,000 5,486,000,000 -15,763,476,000 -15,246,476,000 403,491,648,000
Farmers Capital Bank (FFKT) 402,754,959,000 8.9 0% 10,900,000,000,000 1,434,070,000,000 0 0 15,694,000,000 34,787,000,000 309,508,958,000
Keryx Biopharmaceuticals (KERX) 402,245,642,000 0% -4.1 -60% 151,784,000,000 206,003,000,000 94,218,000,000 0 -90,838,000,000 -90,648,000,000 376,099,642,000
TCR2 Therapeutics (TCRR) 398,883,840,000 -17.3 -11% 190,260,000,000 7,624,000,000 0 0 -20,966,000,000 -20,666,000,000 357,613,839,000
ETFS Precious Metals Basket Trust (GLTR) 382,284,528,000 6.5 15% 379,803,000,000 188,000,000 0 0 58,474,000,000 58,474,000,000 382,284,528,000
Alfacourse (ALFA) 381,330,950,000 0% -23,847.8 -345% 4,636,000 15,473,000 5,875,000 0 -15,990,000 -15,990,000 381,326,743,000
Charter Financial (CHFN) 381,167,323,000 7.4 1% 1,625,835,302,000 1,401,428,650,000 0 0 16,852,418,000 35,949,383,000 265,269,370,000
Hennessy Capital Acquisition III (HCAC) 377,840,323,000 0% -23.7 -15% 421,266,000,000 463,661,000,000 582,505,000,000 0 -64,429,000,000 -30,680,000,000 727,370,323,000
Semler Scientific (SMLR) 357,642,604,000 88% 44.3 75% 9,824,000,000 3,603,000,000 20,293,000,000 17,897,000,000 7,329,000,000 7,970,000,000 353,460,603,000
Gulfmark Offshore (GLF) 354,229,140,000 0% 26.1 -6% 417,402,000,000 135,430,000,000 78,633,000,000 0 -27,052,000,000 15,946,000,000 416,697,140,000
PHH (PHH) 354,128,361,000 0% -0.2 -10% 1,442,000,000,000 953,000,000,000 315,000,000,000 0 -138,000,000,000 -149,000,000,000 37,128,361,000
Government Properties Income Trust (GOV) 349,784,738,000 0% 1.3 -2% 4,804,322,000,000 3,107,836,000,000 176,032,000,000 0 -88,899,000,000 255,390,000,000 325,099,737,000
Nuzee (NUZE) 346,483,290,000 8% -23.3 -247% 6,056,516,000 984,330,000 1,674,689,000 128,528,000 -14,953,892,000 -14,780,993,000 343,685,834,000
JEM Capital (JEM) 345,931,500,000 -4,033.1 -13,053% 660,000 110,820,000 0 0 -86,149,000 -85,774,000 345,931,335,000
Fellazo (FLLZ) 345,056,000,000 -2,070.3 -807% 20,648,000 680,395,000 0 0 -166,669,000 -166,669,000 345,056,000,000
Kraig Biocraft Laboratories (KBLB) 342,650,874,000 0% -263.9 -124% 1,276,033,000 5,343,298,000 140,761,000 0 -1,581,701,000 -1,296,092,000 341,976,645,000

Balance Sheet ($)
Cash
Accounts Receivable
Inventory
PP&E
Assets
Accounts Payable
Long-Term Debt
Liabilities
Stockholders' Equity
Income Statement ($)
Revenue
Cost of Revenue
Gross Profit
R&D
SG&A
Tax
Net Income
Cash Flow ($)
Cash Operating
Cash Investing
Cash Financing